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Abstract
OBJECTIVE: To investigate the effect of Yiguanjian
(YGJ) cataplasm on the development of opioid de-
pendence in a mouse model of naloxone-induced
opioid withdrawal syndrome.
METHODS: One hundred Swiss albino mice, of
equal male to female ratio, were randomly and
equally divided into 10 groups. A portion (3 cm2) of
the backside hair of the mice was removed 1 day
prior to the experiment. Morphine (5 mg/kg) was
intraperitoneally administered twice daily for 5
days. YGJ cataplasm was prepared and pasted on
the bare region of the mice immediately before
morphine administration on day 3 and subsequent-
ly removed at the end day 5. On day 6, naloxone (8
mg/kg) was intraperitoneally injected to precipi-
tate opioid withdrawal syndrome. Behavioral obser-
vation was performed in two 30-min phases imme-
diately after naloxone injection.
RESULTS: The YGJ cataplasm significantly and
dose-dependently attenuated morphine-nalox-
one-induced experimental opioid withdrawal, in
terms of withdrawal severity score and the frequen-
cies of jumping, rearing, forepaw licking, and cir-
cling behaviors. However, YGJ cataplasm treatment
did not alter the acute analgesic effect of morphine.
CONCLUSION: YGJ cataplasm could attenuate opi-
oid dependence and its associated withdrawal
symptoms. Therefore, YGJ cataplasm could serve as
a potential therapy for opioid addiction in the fu-
ture.
Key words: Yi Guan Jian; Paste; Morphine; Nalox-
one; Opioid dependence
INTRODUCTION
Opioid drugs are used primarily for pain control and
can produce a state of euphoria or well-being during
their use. Owing to these mood-enhancing effects, opi-
oid drugs have become the most commonly abused
psychoactive substances worldwide. Continuous ad-
ministration of opioid drugs can elicit opioid depen-
dence, while their abrupt withdrawal may result in the
precipitation of an abstinence syndromes.1 Opioid de-
pendence is usually associated with serious medical, le-
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gal, social problems, and is associated with comorbid
psychiatric disorders. In 2002, the cost of opioid de-
pendence to society was approximately 181 billion US
dollars.2
Until now, several approaches have been proposed for
the management of opioid dependence. Opioid replace-
ment therapy is an effective method in preventing
acute withdrawal and maintaining long-term absti-
nence; however, acceptance of this therapy has been
rather slow.3 Other treatment approaches, such as the
administration of α2-adrenergic agonists, were also ex-
amined in previous studies.4 Unfortunately, none of
these therapies have promised to conclusively treat opi-
oid dependence and its related abstinence syndromes.
Therefore, new approaches for the management of opi-
oid dependence are urgently needed.
Traditional Chinese Medicine (TCM) has been applied
in medical care throughout East Asia for thousands of
years.5,6 Although the active ingredients in most mixed
herbal formulas/medications have not been fully identi-
fied, it has been widely recognized that synergism
among all components within the prescription is an im-
portant characteristic.7,8 The Yiguanjian recipe (YGJ) is
a traditional Chinese herbal formula that possesses the
medical function of nourishing liver-Yin and dispers-
ing stagnated liver-Qi. It has been widely used in Chi-
na for the treatment of diseases with liver-Yin deficien-
cy.9-11 We found that liver-Yin deficiency was a com-
mon clinical syndrome of TCM in opioid dependence
in clinical examinations. Therefore, we examined the
use of YGJ for the treatment of opioid dependence and
showed good effect.
Transdermal drug delivery refers to the topical applica-
tion of drugs to healthy intact skin, either for localized
treatment or systemic therapy.12 The potential of skin
to serve as a pathway for drug administration has al-
ready been demonstrated previously.13 Compared with
conventional drug administration routes, the transder-
mal drug delivery system (TDDS) has several addition-
al advantages. It can maintain constant drug levels in
the blood, while minimizing first-pass metabolism asso-
ciated with gastro-intestinal administration of
drugs.14-16 It is more convenient and has increased pa-
tient compliance compared with oral administration
routes. To date, the transdermal drug delivery of tradi-
tional herbal medicine has been used to treat many dis-
eases.17
In this study, we established a mouse model of nalox-
one-induced opioid withdrawal syndrome and ana-
lyzed the effectiveness of YGJ cataplasm in treating opi-
oid dependence.
MATERIALS ANDMETHODS
Preparation of YGJ cataplasm
The YGJ formula consists of Dihuang (Radix Rehman-
niae), Beishashen (Radix Glehniae), Danggui (Radix An-
gelicae Sinensis), Maidong (Radix Ophiopogonis Japoni-
ci), Gouqizi (Fructus Lycii), Dangshen (Radix Codonop-
sis) and Baizhu (Rhizoma Atractylodis Macrocephalae).
All crude herbs were the products of Jianlian TCM
Co., Ltd. (Jinan, China).7 The herbs were chopped
finely and extracted twice with 10-fold 75% ethanol
(Tianjin Guangcheng Chemical Reagent Co., Ltd.,
Tianjin, China) under reflux. The 75% ethanol extract
was then filtered through absorbent gauze, and the fil-
trate was concentrated under reduced pressure to re-
move the ethanol and produce the dried extract pow-
der. Then, the extract powder, artificial moschus (Bei-
jing Lianxin Pharmaceutic Co., Ltd., Beijing, China),
emodin (Shanghai Yantuo Biosciences Co., Ltd.,
Shanghai, China) and borneol (Hebei Jinmu Pharma-
ceutic Group Co., Ltd., Hebei, China) were mixed in-
to a cream with excipients, including plasdone K-90,
polyplasdone XL-10, and viscomate NP700 (Guang-
zhou Biours Biosciences Co., Ltd., Guangzhou, Chi-
na), according to the requirements of the medicinal
paste detailed in the Pharmacopoeia of the People's Re-
public of China.17 The cream was then coated onto rub-
berized fabric with herb extract powders at a concentra-
tion of 1 mg/cm2 and the resulting plaster was cut into
1 cm2, 2 cm2 and 3 cm2 pieces, which were stored in
desiccators until use.18 The procedure generally corre-
sponded to the pharmaceutical quality standards cur-
rently under the guidance of pharmaceutical experts
from Qilu Hospital of Shandong University. The man-
ufacturing procedure of placebo cataplasm was the
same as that of YGJ cataplasm. The placebo cataplasm
contained all of the excipients that were used in YGJ
cataplasm without the herb extracts.
Animals
One hundred Swiss albino mice of specific patho-
gen-free grade (50 males and 50 females), aged 7 weeks
old, weighing (25 ± 2) g, were used in this study. The
mice were obtained from the Laboratory Animal Cen-
ter of Shandong University (Certificate of quality num-
ber: SCXK [Lu] 20090001). The mice were fed on
standard laboratory diet and tap water and were
housed in the Laboratory Animal Center of Shandong
University. The mice were divided into 10 groups us-
ing a random number table method. The experiments
were conducted in a semi-soundproof laboratory. The
mice were exposed to a 12 h/12 h light/dark cycle,
with the light period between 08：00 to 20：00 h. Be-
haviors were observed using a 30 cm3 large transparent
Perspex observation chamber. Two observers who were
blind to the treatment schedule simultaneously ob-
served the withdrawal measurements. The mean value
of both observations was recorded. The experimental
protocol was performed in accordance with the Institu-
tional Animal Ethics Committee. The study was ap-
proved by the local Research and Ethics Committee at
Qilu Hospital of Shandong University, in accordance
with the guidelines of the 1975Declaration ofHelsinki.
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Drugs and chemicals
Morphine was obtained from Shandong Public Securi-
ty Bureau, Jinan, China. Naloxone (Bejing Kewin Tech-
nology Share-holding Co., Ltd., Beijing, China) was
obtained from Qilu Hospital of Shandong University.
Naloxone and morphine were diluted in normal saline
(China Otsuka Pharmaceutical Co., Ltd., Tianjin, Chi-
na) immediately before use.
Induction of opioid withdrawal syndromes in mice
A 3 cm2 section of hair was removed on the backside of
the mice, using hair removal cream, 1 day prior to the
initiation of the experiment. Morphine (5 mg/kg) was
intraperitoneally administered twice daily (at 08：00
and 20：00 h) for 5 days. Cataplasm was pasted on the
bare backside of the mice immediately before mor-
phine administration on day 3 and removed at the end
of day 5. On day 6, 8 mg/kg naloxone was intraperito-
neally injected at 10：00 h to precipitate withdrawal
syndrome. Behavioral observation was performed in
two 30-min phases immediately after injecting nalox-
one.18-20 The first 30-min observation period, immedi-
ately after naloxone administration, was used to assess
jumping frequency and withdrawal severity score. The
second 30-min observation period was used to assess
the frequency of rearing, forepaw licking, and circling
behaviors.
Assessment of jumping frequency
Repeated jumping behavior precipitated by naloxone
was considered as a predominant sign of opioid with-
drawal syndrome in the mice.20,21 A jumping response
was defined as a spring or leap off the surface by a mus-
cular effort of the legs and feet.
Assessment of withdrawal severity score (WSS)
WSS was used to quantify the withdrawal syndrome in
each mouse, which included the following behaviors:
forepaw tremors, wet dog shake, straightening, ptosis
and sneezing.22-24 The severity of each behavior was re-
corded in terms of both magnitude and frequency dur-
ing the observation period. The scores were recorded as
follows: 0, no change; 1, mild increase; 2, moderate in-
crease; and 3, severe increase. A cumulative withdrawal
severity score of the five component scores was ob-
tained.
Assessment of rearing, forepaw licking and circling
frequency
Rearing, forepaw licking and circling frequency obser-
vations were observed as a measure of the behavioral
aberration severity ascribed to experimental opioid
withdrawal in mice.25-27 Rearing was defined as repeti-
tive rising of the frontal aspect of the mouse body
while balancing the body on the hind limbs. Forepaw
licking was defined as the mouse licking both of its
forepaws at least once. Circling was defined as the com-
pletion of a complete circle of the entire observation
chamber.
Measurement of the effect of YGJ cataplasm on
nociceptive threshold using the tail-flick test
The tail-flick test was used to measure the nociceptive
threshold in mice.20,21,28 The tail-flick latency was regard-
ed as the time between tail exposure to radiant heat
and tail withdrawal. Electrically-heated nichrome wire
was used as the radiant heat source in our study. The
intensity of radiant heat was modulated to obtain pre-
treatment latency between 2-3 s. The cut-off latency
time was fixed at 10 s. Tail-flick latency was expressed
as a percentage of the maximum possible effect (MPE),
as follows:
MPE (%) = 100 × (posttreatment latency-pretreatment
latency) / (cut off time − pretreatment latency)
The peak time for morphine was 30 min after adminis-
tration. Therefore, we observed tail-flick latency imme-
diately before and at 30 min after morphine adminis-
tration.
Experimental protocol
The experimental protocols are shown in the following
section. Ten groups of mice were employed in our
study, with each group comprising of 10 animals (5
male, 5 female).
Group Ⅰ (vehicle-vehicle control): vehicle for mor-
phine (saline, 10 mL/kg, i.p.) twice daily + placebo cat-
aplasm (2 cm2) for 3 days + vehicle for naloxone (sa-
line, 10 mL/kg, i.p.) on day 6.
Group Ⅱ (vehicle-naloxone control): vehicle for mor-
phine (saline, 10 mL/kg, i.p.) twice daily + placebo cat-
aplasm (2 cm2) for 3 days + naloxone (8 mg/kg, i.p.)
on day 6.
Group Ⅲ (morphine-naloxone control): morphine
(5 mg/kg, i.p.) twice daily + placebo cataplasm (2 cm2)
for 3 days + naloxone (8 mg/kg, i.p.) on day 6.
Group Ⅳ (YGJ cataplasm + vehicle-naloxone control):
vehicle for morphine (saline, 10 mL/kg, i.p.) twice dai-
ly + YGJ cataplasm (2 cm2) for 3 days + naloxone
(8 mg/kg, i.p.) on day 6.
Group Ⅴ-Ⅶ (YGJ cataplasm + morphine-naloxone):
morphine (5 mg/kg, i.p.) twice daily + YGJ cataplasm
(1, 2, 3 cm2 for groupsⅤ,Ⅵ, andⅦ, respectively) for
3 days + naloxone (8 mg/kg, i.p.) on day 6.
Group Ⅷ (morphine analgesia group): morphine
(5 mg/kg, i.p) only.
Group Ⅸ (vehicle-morphine analgesia group): Each
mouse was treated with placebo cataplasm (2 cm2) for
3 days prior to morphine administration (5 mg/kg, i.p).
Group Ⅹ (YGJ cataplasm-morphine analgesia group):
each mouse was treated with YGJ cataplasm (2 cm2) for
3 days prior tomorphine administration (5mg/kg, i.p).
Although Groups Ⅱ and Ⅳ were not involved in the
statistical analysis, we still considered it necessary to in-
clude them as control groups to ensure the rigorous-
ness of study and the accuracy of data compared with
several previous studies.20,21
Statistical analyses All results were expressed as means ±
standard deviation ( xˉ ± s). The data were analyzed us-
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Figure 1 Effect of YGJ cataplasm on naloxone-induced jumping frequency in different groups
GroupⅠ (vehicle-vehicle control): saline, 10 mL/kg, i.p. twice daily + placebo cataplasm (2 cm2) for 3 days + saline, 10 mL/kg, i.p.
on day 6. GroupⅡ (vehicle-naloxone control): saline, 10 mL/kg, i.p. twice daily + placebo cataplasm (2 cm2) for 3 days + naloxone
(8 mg/kg, i.p.) on day 6. GroupⅢ (morphine-naloxone control): morphine (5 mg/kg, i.p.) twice daily + placebo cataplasm (2 cm2)
for 3 days + naloxone (8 mg/kg, i.p.) on day 6. GroupⅣ (YGJ cataplasm + vehicle-naloxone control): saline, 10 mL/kg, i.p. twice
daily + YGJ cataplasm (2 cm2) for 3 days + naloxone (8 mg/kg, i.p.) on day 6. GroupⅤ-Ⅶ (YGJ cataplasm + morphine-naloxone):
morphine (5 mg/kg, i.p.) twice daily + YGJ cataplasm (1, 2, 3 cm2 for groupsⅤ,Ⅵ, andⅦ, respectively) for 3 days + naloxone (8
mg/kg, i.p.) on day 6. YGJ: Yiguanjian. aP < 0.05 vs GroupⅠ; b,c,dP < 0.05 vs GroupⅢ. The jumping frequencies of GroupⅠ,Ⅱ, andⅣwere 0.
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ing SPSS software (version 16.0, SPSS Inc., Chicago,
IL, USA). One-way analysis of variance followed by
Tukey's post-hoc analysis was used to analyze the differ-
ence among variables between groups. P < 0.05 was
considered statistically significant.
RESULTS
Jumping behavior
There was significant difference (P < 0.01) in jumping
frequencies between Group Ⅲ (16.50 ± 2.64) and
Group Ⅰ (0.00 ± 0.00). Meanwhile, YGJ cataplasm
(1, 2, 3 cm2) significantly (all P < 0.01) and dose-de-
pendently (all P < 0.05) decreased jumping frequencies
in opioid-dependent mice (Figure 1).
WSS
There was a significant difference (P < 0.01) in WSSs
between GroupⅢ (12.60 ± 1.71) and GroupⅠ (0.00
± 0.00). Meanwhile, YGJ cataplasm (1, 2, 3 cm2) signif-
icantly (all P < 0.01) and dose-dependently (all P <
0.05) decreased the WSSs in opioid-dependent mice
(Figure 2).
Rearing frequency
There was a significant difference (P < 0.01) in rearing
frequencies between Group Ⅲ (26.20 ± 1.81) and
Group Ⅰ (0.00 ± 0.00). Meanwhile, YGJ cataplasm
(1, 2, 3 cm2) significantly (all P < 0.01) and dose-de-
pendently (all P < 0.05) decreased the rearing frequen-
cy in opioid-dependent mice (Figure 3).
Forepaw licking frequency
There was a significant difference (P < 0.01) in fore-
paw licking frequencies between Group Ⅲ (9.00 ±
1.16) and Group Ⅰ (0.00 ± 0.00). Meanwhile, YGJ
cataplasm (1, 2, 3 cm2) significantly (all P < 0.01) and
dose-dependently (all P < 0.05) decreased the forepaw
licking frequency in opioid-dependent mice (Figure 4).
Circling frequency
There was significant difference (P < 0.01) in circling
frequencies between Group Ⅲ (24.60 ± 6.35) and
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Figure 2 Effect of YGJ cataplasm on naloxone-induced withdrawal severity score in different groups
GroupⅠ (vehicle-vehicle control): saline, 10 mL/kg, i.p. twice daily + placebo cataplasm (2 cm2) for 3 days + saline, 10 mL/kg, i.p.
on day 6. GroupⅡ (vehicle-naloxone control): saline, 10 mL/kg, i.p. twice daily + placebo cataplasm (2 cm2) for 3 days + naloxone
(8 mg/kg, i.p.) on day 6. GroupⅢ (morphine-naloxone control): morphine (5 mg/kg, i.p.) twice daily + placebo cataplasm (2 cm2)
for 3 days + naloxone (8 mg/kg, i.p.) on day 6. GroupⅣ (YGJ cataplasm + vehicle-naloxone control): saline, 10 mL/kg, i.p. twice
daily + YGJ cataplasm (2 cm2) for 3 days + naloxone (8 mg/kg, i.p.) on day 6. GroupⅤ-Ⅶ (YGJ cataplasm + morphine-naloxone):
morphine (5 mg/kg, i.p.) twice daily + YGJ cataplasm (1, 2, 3 cm2 for groupsⅤ,Ⅵ, andⅦ, respectively) for 3 days + naloxone (8
mg/kg, i.p.) on day 6. aP < 0.05 vs Group I; b,c,dP < 0.05 vs GroupⅢ. YGJ: Yiguanjian. The withdrawal severity scores of GroupⅠ,Ⅱ,
andⅣwere 0.
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Figure 3 Effect of YGJ cataplasm on naloxone-induced rearing frequency in different groups
GroupⅠ (vehicle-vehicle control): saline, 10 mL/kg, i.p. twice daily + placebo cataplasm (2 cm2) for 3 days + saline, 10 mL/kg, i.p.
on day 6. GroupⅡ (vehicle-naloxone control): saline, 10 mL/kg, i.p. twice daily + placebo cataplasm (2 cm2) for 3 days + naloxone
(8 mg/kg, i.p.) on day 6. GroupⅢ (morphine-naloxone control): morphine (5 mg/kg, i.p.) twice daily + placebo cataplasm (2 cm2)
for 3 days + naloxone (8 mg/kg, i.p.) on day 6. GroupⅣ (YGJ cataplasm + vehicle-naloxone control): saline, 10 mL/kg, i.p. twice
daily + YGJ cataplasm (2 cm2) for 3 days + naloxone (8 mg/kg, i.p.) on day 6. GroupⅤ-Ⅶ (YGJ cataplasm + morphine-naloxone):
morphine (5 mg/kg, i.p.) twice daily + YGJ cataplasm (1, 2, 3 cm2 for groupsⅤ,Ⅵ, andⅦ, respectively) for 3 days + naloxone (8
mg/kg, i.p.) on day 6. YGJ: Yiguanjian. aP < 0.05 vs Group I; b,c,dP < 0.05 vs GroupⅢ. The rearing frequencies of GroupⅠ,Ⅱ, andⅣ
were 0.
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Figure 4 Effect of YGJ cataplasm on naloxone-induced forepaw licking frequency in different groups
GroupⅠ (vehicle-vehicle control): saline, 10 mL/kg, i.p. twice daily + placebo cataplasm (2 cm2) for 3 days + saline, 10 mL/kg, i.p.
on day 6. GroupⅡ (vehicle-naloxone control): saline, 10 mL/kg, i.p. twice daily + placebo cataplasm (2 cm2) for 3 days + naloxone
(8 mg/kg, i.p.) on day 6. GroupⅢ (morphine-naloxone control): morphine (5 mg/kg, i.p.) twice daily + placebo cataplasm (2 cm2)
for 3 days + naloxone (8 mg/kg, i.p.) on day 6. GroupⅣ (YGJ cataplasm + vehicle-naloxone control): saline, 10 mL/kg, i.p. twice
daily + YGJ cataplasm (2 cm2) for 3 days + naloxone (8 mg/kg, i.p.) on day 6. GroupⅤ-Ⅶ (YGJ cataplasm + morphine-naloxone):
morphine (5 mg/kg, i.p.) twice daily + YGJ cataplasm (1, 2, 3 cm2 for groupsⅤ,Ⅵ, andⅦ, respectively) for 3 days + naloxone (8
mg/kg, i.p.) on day 6. YGJ: Yiguanjian. aP < 0.05 vs Group I; b,c,dP < 0.05 vs GroupⅢ. The forepaw licking frequencies of GroupⅠ,Ⅱ,
andⅣwere 0.
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Figure 5 Effect of YGJ cataplasm on naloxone-induced circling frequency in different groups
GroupⅠ (vehicle-vehicle control): saline, 10 mL/kg, i.p. twice daily + placebo cataplasm (2 cm2) for 3 days + saline, 10 mL/kg, i.p.
on day 6. GroupⅡ (vehicle-naloxone control): saline, 10 mL/kg, i.p. twice daily + placebo cataplasm (2 cm2) for 3 days + naloxone
(8 mg/kg, i.p.) on day 6. GroupⅢ (morphine-naloxone control): morphine (5 mg/kg, i.p.) twice daily + placebo cataplasm (2 cm2)
for 3 days + naloxone (8 mg/kg, i.p.) on day 6. GroupⅣ (YGJ cataplasm + vehicle-naloxone control): saline, 10 mL/kg, i.p. twice
daily + YGJ cataplasm (2 cm2) for 3 days + naloxone (8 mg/kg, i.p.) on day 6. GroupⅤ-Ⅶ (YGJ cataplasm + morphine-naloxone):
morphine (5 mg/kg, i.p.) twice daily + YGJ cataplasm (1, 2, 3 cm2 for groupsⅤ,Ⅵ, andⅦ, respectively) for 3 days + naloxone (8
mg/kg, i.p.) on day 6. YGJ: Yiguanjian. aP < 0.05 vs GroupⅠ; b,c,dP < 0.05 vs GroupⅢ. The circling frequencies of GroupⅠ,Ⅱ, andⅣwere 0.
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Group Ⅰ (0.00 ± 0.00). Meanwhile, YGJ cataplasm
(1, 2, 3 cm2) significantly (all P < 0.01) and dose-de-
pendently (all P < 0.05) decreased the circling frequen-
cy in opioid-dependent mice (Figure 5).
Morphine-induced analgesia
We performed the tail-flick test to confirm that YGJ
cataplasm did not possess antinociceptive effects. There
were no significant difference (all P > 0.05) in the
MPE in among GroupsⅧ (53.96 ± 2.79),Ⅸ (50.89 ±
4.80) andⅩ (52.45 ± 5.05).
DISCUSSION
In our study, we analyzed the effect of YGJ cataplasm
for treating opioid dependence in a mouse model of
naloxone-induced opioid withdrawal syndrome. We
found that YGJ cataplasm significantly and dose-de-
pendently decreased the jumping frequency, WSS, rear-
ing frequency, forepaw licking frequency and circling
frequency in opioid-dependent mice. Furthermore, the
tail-flick test showed that YGJ cataplasm did not alter
the antinociceptive activity of morphine.
Tolerance refers to the decreased effect of a drug after
repeated administration, requiring higher doses to re-
ceive similar effects. Withdrawal syndrome is character-
ized by a series of emotional, physical, and behavioral
changes after discontinuing certain drugs.29 The emer-
gence of tolerance and withdrawal symptoms is com-
mon when opioid analgesics and other illicit opiates
are used. Recently, the treatment of opioid dependence
has mainly depended on opiate replacement therapy
and symptomatic treatment of withdrawal signs.
TCM has been practiced in China for more than 2000
years, and for the past 200 years it has been used in the
treatment of drug addiction. Until now, at least 10 Chi-
nese medicines have been approved for the treatment
of opiate addiction by the Chinese State Food and
Drug Administration.30,31 We found that liver-Yin defi-
ciency was a common clinical syndrome of TCM in
opioid dependence in clinical examinations. YGJ was
established by Wei Zhixian in the Qing Dynasty (AD
1722-1772) and was first recorded in medical practice
in Liu Zhou, a classic liver-Yin tonifying herbal formu-
la, while YGJ is commonly used for treating diseases
with liver-Yin deficiency.9-11 Therefore, we examined
the efficacy of YGJ cataplasm in treating opioid depen-
dence in this study. After analysis, we found that YGJ
cataplasm could significantly and dose-dependently at-
tenuate opioid withdrawal syndrome in mice, in terms
of WSS, and the frequencies of jumping, rearing, fore-
paw licking, and circling behaviors.
In our study, we used TDDS for the administration of
drugs. TDDS had many advantages over alternative
methods of drug administration. It had better patient
compliance than conventional drug administration
routes, such as oral delivery. It can distribute certain
drugs in the systemic circulation in a more convenient
and effective way, and maintain constant blood drug
levels for long time periods. Meanwhile, drugs can be
delivered directly to blood circulation without undergo-
ing first-pass metabolism through TDDS.
Our study also had several limitations. We demonstrat-
ed that YGJ cataplasm might attenuate opioid depen-
dence and its withdrawal syndrome; however, we did
not reveal the detailed mechanism underlying how this
was achieved. This mechanism might be elucidated in
our future studies, in which we might also compare the
effect of YGJ cataplasm and other recently-developed
drugs for treating opioid dependence and its withdraw-
al syndrome. As a famous TCM formula, the YGJ cata-
plasm has been used in clinical applications for many
years in China. Therefore, we might analyze the effica-
cy of YGJ cataplasm for treating opioid dependence in
clinical studies in the future.
In conclusion, we found that YGJ cataplasm might at-
tenuate opioid dependence and its withdrawal syn-
dromes in a mouse model of naloxone-induced opioid
withdrawal syndrome. YGJ cataplasm might serve as a
potential therapy for combating opioid addiction in
the future.
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